Left ventricular hypertrophy in hypertension: a systematic review and meta-analysis of echocardiographic studies published from 2011 to 2025.

J HypertensJul 27, 2026 (epub)
Clinical ResearchCardiology

Elisa Gherbesi, Andrea Faggiano, Carla Sala et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the prevalence of left ventricular hypertrophy (LVH) in 74,632 hypertensive patients from studies published between 2011 and 2025. The analysis found an overall LVH prevalence of 36.6% (95% CI: 33.4-40%). It highlighted significant gender differences, with men having a lower probability of LVH compared to women (OR=0.62, CI: 0.48-0.80, P<0.0001).

Key findings

  • The overall prevalence of LVH in hypertensive patients was 36.6% (95% CI: 33.4-40%).
  • Men had a lower probability of LVH compared to women (OR=0.62, CI: 0.48-0.80, P<0.0001).
  • The risk of concentric LVH was almost twice as high as eccentric LVH (OR=1.94, CI: 1.52-2.49, P<0.0001).

Why it matters

The high prevalence of LVH indicates ongoing challenges in managing hypertension and preventing hypertensive heart disease. Understanding these patterns can guide clinicians in tailoring treatment strategies, particularly for at-risk populations such as women.

Source

PubMed · PMID 42554265

Published in J Hypertens. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.